No Prescription |
 |
 | ||
|
STAVIR Zerit |
|
| ||
No Prescription » Prescription Drugs 15 » STAVIR Zerit Stavudine is used in combination with other antiviral medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Stavudine is in a class of antiviral medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs). It works by slowing the spread of HIV in the body. Stavudine does not cure HIV and may not prevent you from developing HIV-related illnesses. Stavudine does not prevent the spread of HIV to other people.Stavudine is also sometimes used in combination with other medications to prevent HIV infection in health care workers or other people who were accidentally exposed to HIV. Talk to your doctor about the possible risks of using this medication for your condition. Buy STAVIR Zerit and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About STAVIR Zerit: Product Type: Prescription Drugs 15 STAVIR ( Zerit d4T Generic Stavudine ) STAVIR (Zerit d4T Generic Stavudine) Zerit d4T Generic Stavudine 30mg Caps Zerit d4T Generic Stavudine STAVIR
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
